APA (7th ed.) Citation

N, A., L, F., JR, W., FB, H., HJ, L., L, F., . . . LJ, N. (2025). A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma. Blood advances, 9(17), 4396. https://doi.org/10.1182/bloodadvances.2025016483

Chicago Style (17th ed.) Citation

N, Akkad, et al. "A Phase 2 Study of Obinutuzumab Combined with Lenalidomide in Previously Untreated High Tumor Burden Follicular Lymphoma." Blood Advances 9, no. 17 (2025): 4396. https://doi.org/10.1182/bloodadvances.2025016483.

MLA (9th ed.) Citation

N, Akkad, et al. "A Phase 2 Study of Obinutuzumab Combined with Lenalidomide in Previously Untreated High Tumor Burden Follicular Lymphoma." Blood Advances, vol. 9, no. 17, 2025, p. 4396, https://doi.org/10.1182/bloodadvances.2025016483.